Takeda Pharmaceutical Q2 2024 GAAP EPS ¥134.00 Up From ¥111.00 YoY, Sales ¥.176T Beat ¥1.084T Estimate
Takeda Pharmaceutical Q2 2024 GAAP EPS ¥134.00 Up From ¥111.00 YoY, Sales ¥.176T Beat ¥1.084T Estimate
武田製藥2024年第二季度按照美國通用會計準則的每股收益爲134.00日元，較去年同期的111.00日元有所提高，銷售額爲176萬億日元，超過1.084萬億日元的預估
Takeda Pharmaceutical (NYSE:TAK) reported quarterly earnings of ¥134.00 per share. This is a 20.72 percent increase over earnings of ¥111.00 per share from the same period last year. The company reported quarterly sales of ¥1.176 trillion which beat the analyst consensus estimate of ¥1.084 trillion by 8.48 percent. This is a 12.75 percent increase over sales of ¥1.043 trillion the same period last year.
武田製藥（紐交所：TAK）報告每股收益爲134.00日元。這比去年同期每股收益111.00日元增加了20.72％。公司報告的季度銷售額爲1.176萬億日元，超過了分析師對1.084萬億日元的一致預期，增幅爲8.48％。這比去年同期銷售額1.043萬億日元增長了12.75％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間